US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Soligenix, Inc.

0.3448

+0.00682.01%

Volume:1.21M

Turnover:401.34K

Market Cap:3.55M

PE:-0.16

High:0.3464

Open:0.3301

Low:0.3157

Close:0.3380

52wk High:6.23

52wk Low:0.3157

Shares:10.31M

Float Shares:9.76M

Volume Ratio:0.36

T/O Rate:12.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1400

EPS(LYR):-4.9786

ROE:-235.50%

ROA:-81.35%

PB:0.67

PE(LYR):-0.07

Loading ...

Overview Company News Filings

Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility

Soligenix Inc - Phase 3 Flash2 Trial of Hybryte in Ctcl Recommended to Halt for Futility

THOMSON REUTERS

Soligenix Announces Interim Results From the Phase 3 Flash2 Trial Evaluating Hybryte™ in Treatment of Cutaneous T-Cell Lymphoma

THOMSON REUTERS

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach

Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results

Soligenix publishes corporate presentation highlighting late-stage rare disease drug pipeline

Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study

Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate

Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary

Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue

Wall Street Analysts Are Bullish on Top Healthcare Picks

BRIEF-Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results

Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales

Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Soligenix shares rise; European Commission grants orphan drug designation for SGX945 in Behçet's disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":0.3448,"timestamp":1777575989568,"preClose":0.338,"halted":0,"volume":1212314,"delay":0,"changeRate":0.02011834319526619,"floatShares":9760500,"shares":10306079,"eps":-2.14,"marketStatus":"Trading","change":0.0068,"latestTime":"04-30 15:07:13 EDT","open":0.3301,"high":0.3464,"low":0.3157,"amount":401338.51364868,"amplitude":0.090828,"askPrice":0.345,"askSize":100,"bidPrice":0.3446,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.14,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777579200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.338,"preHourTrading":{"tag":"盘前","latestPrice":0.331,"preClose":0.338,"latestTime":"09:27 EDT","volume":23408,"amount":7835.290786400001,"timestamp":1777555670021,"change":-0.007,"changeRate":-0.02071,"amplitude":0.034615},"postHourTrading":{"tag":"盘后","latestPrice":0.3306,"preClose":0.338,"latestTime":"19:49 EDT","volume":130862,"amount":43824.484154,"timestamp":1777506587525,"change":-0.0074,"changeRate":-0.021893,"amplitude":0.058876},"volumeRatio":0.359308},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":9760500,"roa":"-81.35%","roe":"-235.50%","lyrEps":-4.978626,"volumeRatio":0.359308,"shares":10306079,"dividePrice":0,"high":0.3464,"amplitude":0.090828,"preClose":0.338,"low":0.3157,"week52Low":0.3157,"pbRate":"0.67","week52High":6.2299,"institutionHeld":0.0284,"latestPrice":0.3448,"eps":-2.14,"divideRate":0,"volume":1212314,"delay":0,"ttmEps":-2.14,"open":0.3301,"prevYearClose":1.34,"prevWeekClose":1.39,"prevMonthClose":1.18,"prevQuarterClose":1.18,"fiveDayClose":1.37,"twentyDayClose":1.15,"sixtyDayClose":1.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"date":"2026-03-31","symbol":"SNGX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-Market","dateTimestamp":1774929600000,"actualEps":null},{"market":"US","date":"2025-11-07","symbol":"SNGX","fiscalQuarterEnding":"2025/09","expectedEps":-0.63,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-08-14","symbol":"SNGX","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2025-05-09","symbol":"SNGX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.06},{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1752724800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2026-04-29","current":-0.157991,"percent":0.969943,"low":-4.210471,"twenty":-2.144309,"median":-1.153665,"eighty":-0.61561,"high":-0.277411,"avg":-1.422761,"sd":0.91572,"marketCap":4337828},"quantilePoints":[{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-05-02","current":-0.732922,"twenty":-3.335701,"median":-1.677345,"eighty":-0.767341,"marketCap":6058757},{"date":"2025-05-09","current":-0.752009,"twenty":-3.318337,"median":-1.658339,"eighty":-0.75921,"marketCap":6216537},{"date":"2025-05-16","current":-0.625327,"twenty":-3.306695,"median":-1.64132,"eighty":-0.752009,"marketCap":5995645},{"date":"2025-05-23","current":-0.623044,"twenty":-3.300954,"median":-1.631589,"eighty":-0.744363,"marketCap":5973753},{"date":"2025-05-30","current":-0.653685,"twenty":-3.291097,"median":-1.613804,"eighty":-0.737916,"marketCap":6267544},{"date":"2025-06-06","current":-0.626449,"twenty":-3.282404,"median":-1.587127,"eighty":-0.732937,"marketCap":6006396},{"date":"2025-06-13","current":-0.626449,"twenty":-3.276897,"median":-1.572151,"eighty":-0.718851,"marketCap":6006396},{"date":"2025-06-20","current":-0.607723,"twenty":-3.27413,"median":-1.559154,"eighty":-0.711081,"marketCap":5826857},{"date":"2025-06-27","current":-0.466432,"twenty":-3.268842,"median":-1.519397,"eighty":-0.698758,"marketCap":4472154},{"date":"2025-07-03","current":-0.408553,"twenty":-3.257603,"median":-1.473383,"eighty":-0.664356,"marketCap":3917215},{"date":"2025-07-11","current":-0.432386,"twenty":-3.236874,"median":-1.452959,"eighty":-0.65419,"marketCap":4145719},{"date":"2025-07-18","current":-0.463027,"twenty":-3.217218,"median":-1.430621,"eighty":-0.643472,"marketCap":4439510},{"date":"2025-07-25","current":-0.473241,"twenty":-3.2141,"median":-1.408221,"eighty":-0.637343,"marketCap":4537440},{"date":"2025-08-01","current":-0.997551,"twenty":-3.188721,"median":-1.381754,"eighty":-0.627362,"marketCap":9564533},{"date":"2025-08-08","current":-1.120117,"twenty":-3.181107,"median":-1.370141,"eighty":-0.627362,"marketCap":10739698},{"date":"2025-08-15","current":-1.000956,"twenty":-3.164793,"median":-1.351886,"eighty":-0.627362,"marketCap":9597177},{"date":"2025-08-22","current":-1.389916,"twenty":-3.149818,"median":-1.351739,"eighty":-0.627362,"marketCap":14399515},{"date":"2025-08-29","current":-1.265816,"twenty":-3.133169,"median":-1.335619,"eighty":-0.627362,"marketCap":13113844},{"date":"2025-09-05","current":-1.257543,"twenty":-3.117677,"median":-1.322798,"eighty":-0.627006,"marketCap":13028132},{"date":"2025-09-12","current":-1.14999,"twenty":-3.103112,"median":-1.30595,"eighty":-0.627362,"marketCap":11913884},{"date":"2025-09-19","current":-1.141717,"twenty":-3.087143,"median":-1.297273,"eighty":-0.627362,"marketCap":11828173},{"date":"2025-09-26","current":-0.670138,"twenty":-3.067674,"median":-1.286016,"eighty":-0.627362,"marketCap":6942623},{"date":"2025-10-03","current":-0.529492,"twenty":-3.01938,"median":-1.275424,"eighty":-0.623501,"marketCap":5485529},{"date":"2025-10-10","current":-1.442653,"twenty":-2.995922,"median":-1.267432,"eighty":-0.616672,"marketCap":14945873},{"date":"2025-10-17","current":-1.249225,"twenty":-2.91443,"median":-1.264341,"eighty":-0.616672,"marketCap":12941957},{"date":"2025-10-24","current":-1.289522,"twenty":-2.875231,"median":-1.264341,"eighty":-0.616672,"marketCap":13359440},{"date":"2025-10-31","current":-1.216987,"twenty":-2.813038,"median":-1.258586,"eighty":-0.616672,"marketCap":12607971},{"date":"2025-11-07","current":-1.031618,"twenty":-2.781244,"median":-1.253152,"eighty":-0.616672,"marketCap":10687552},{"date":"2025-11-14","current":-1.245919,"twenty":-2.740725,"median":-1.250644,"eighty":-0.616672,"marketCap":13918859},{"date":"2025-11-21","current":-1.146607,"twenty":-2.677684,"median":-1.246297,"eighty":-0.616672,"marketCap":12809385},{"date":"2025-11-28","current":-1.435516,"twenty":-2.656351,"median":-1.246297,"eighty":-0.616672,"marketCap":16036946},{"date":"2025-12-05","current":-1.471629,"twenty":-2.625475,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-12","current":-1.471629,"twenty":-2.589141,"median":-1.246297,"eighty":-0.616672,"marketCap":16440391},{"date":"2025-12-19","current":-1.110493,"twenty":-2.546865,"median":-1.242649,"eighty":-0.616672,"marketCap":12405939},{"date":"2025-12-26","current":-1.30009,"twenty":-2.53187,"median":-1.240895,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-02","current":-1.209806,"twenty":-2.515486,"median":-1.23858,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-09","current":-1.30009,"twenty":-2.498557,"median":-1.23858,"eighty":-0.616672,"marketCap":14524027},{"date":"2026-01-16","current":-1.209806,"twenty":-2.489022,"median":-1.236891,"eighty":-0.616672,"marketCap":13515414},{"date":"2026-01-23","current":-1.282033,"twenty":-2.465907,"median":-1.236891,"eighty":-0.616672,"marketCap":14322304},{"date":"2026-01-30","current":-1.182721,"twenty":-2.437573,"median":-1.23371,"eighty":-0.616672,"marketCap":13212830},{"date":"2026-02-06","current":-0.938954,"twenty":-2.392653,"median":-1.223977,"eighty":-0.616672,"marketCap":10489575},{"date":"2026-02-13","current":-0.95701,"twenty":-2.376157,"median":-1.215641,"eighty":-0.616672,"marketCap":10691297},{"date":"2026-02-20","current":-1.002153,"twenty":-2.339841,"median":-1.209806,"eighty":-0.616672,"marketCap":11195604},{"date":"2026-02-27","current":-1.038266,"twenty":-2.333363,"median":-1.202678,"eighty":-0.616672,"marketCap":11599049},{"date":"2026-03-06","current":-1.038266,"twenty":-2.311663,"median":-1.186246,"eighty":-0.616672,"marketCap":11599049},{"date":"2026-03-13","current":-1.101465,"twenty":-2.300249,"median":-1.182902,"eighty":-0.616672,"marketCap":12305078},{"date":"2026-03-20","current":-1.101465,"twenty":-2.274431,"median":-1.177245,"eighty":-0.616672,"marketCap":12305078},{"date":"2026-03-27","current":-1.092437,"twenty":-2.242027,"median":-1.172338,"eighty":-0.616672,"marketCap":12204217},{"date":"2026-04-02","current":-1.04681,"twenty":-2.22985,"median":-1.169515,"eighty":-0.616672,"marketCap":11599049},{"date":"2026-04-10","current":-1.060336,"twenty":-2.208657,"median":-1.163574,"eighty":-0.616672,"marketCap":11748930},{"date":"2026-04-17","current":-1.08824,"twenty":-2.18478,"median":-1.155028,"eighty":-0.616672,"marketCap":12058112},{"date":"2026-04-24","current":-1.274264,"twenty":-2.169144,"median":-1.155028,"eighty":-0.616672,"marketCap":14119328},{"date":"2026-04-29","current":-0.391487,"twenty":-2.144309,"median":-1.153665,"eighty":-0.61561,"marketCap":4337828}],"updateTime":1777570551291},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630066423","title":"Soligenix halts Phase 3 FLASH2 HyBryte trial in CTCL for futility","url":"https://stock-news.laohu8.com/highlight/detail?id=2630066423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630066423?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:30","pubTimestamp":1777375859,"startTime":"0","endTime":"0","summary":"Soligenix reported interim results from pivotal Phase 3 FLASH2 trial of HyBryte in cutaneous T-cell lymphoma.Data Monitoring Committee recommended halting study for futility, citing lack of efficacy signal versus expectations from prior trial.Management plans additional data review to assess whether any patient subgroups may still benefit.Company flagged strategic review, citing about $5.9 million in cash.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL5JCpdW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306998","title":"Soligenix Inc - Phase 3 Flash2 Trial of Hybryte in Ctcl Recommended to Halt for Futility","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630306998?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:30","pubTimestamp":1777375801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA8RKFLP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306994","title":"Soligenix Announces Interim Results From the Phase 3 Flash2 Trial Evaluating Hybryte™ in Treatment of Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630306994?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:30","pubTimestamp":1777375801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA8RKFLP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630003305","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:25 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2630003305","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630003305?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:25","pubTimestamp":1777375500,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:25 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nAQN2LWG24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629055759","title":"Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2629055759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629055759?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:00","pubTimestamp":1776787211,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 21st, 2026, FinanceWire By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-highlights-patient-centric-drug-development-strategy-through-reformulation-approach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-highlights-patient-centric-drug-development-strategy-through-reformulation-approach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQE","MNQmain","NVIW.SI","ONEQ","QQQY","QQQA","NQmain","TQQY","JEPQ","QID","TQQQ","QQQJ","FTEC","QLD","BK4139","GPIQ","IYW","QYLG","NDX","SNGX",".IXIC","SQQQ","QQQM","QDTE","QQQ","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629778564","title":"Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2629778564","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629778564?lang=en_us&edition=fundamental","pubTime":"2026-04-21 02:00","pubTimestamp":1776708011,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 20th, 2026, FinanceWire Designations from established global organizations such as the European Commission carr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-strengthens-pipeline-as-european-commission-grants-sgx945-orphan-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-strengthens-pipeline-as-european-commission-grants-sgx945-orphan-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","QQQA","FTEC","QQQJ","QDTE","IYW","QID","GPIQ","NDX","BK4139","JEPQ","NVIW.SI","TQQQ","QLD","QQQE","SQQQ","QQQM","QQQ","QYLG","SNGX","QQQY","TQQY",".IXIC","MNQmain","PSQ","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628785725","title":"Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2628785725","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628785725?lang=en_us&edition=fundamental","pubTime":"2026-04-18 01:30","pubTimestamp":1776447010,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 17th, 2026, FinanceWire Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL&rd...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-advances-ctcl-research-with-interim-analysis-comparative-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-advances-ctcl-research-with-interim-analysis-comparative-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","ONEQ","BK4139","TQQQ","QYLG","NVIW.SI","QQQ","SNGX","QQQE","QQQJ","TQQY","MNQmain","QQQM","QQQA","IYW","QQQY","QID","JEPQ","QLD","NQmain","QDTE","SQQQ","PSQ","NDX","GPIQ","FTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626927189","title":"Soligenix publishes corporate presentation highlighting late-stage rare disease drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2626927189","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626927189?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:55","pubTimestamp":1775681742,"startTime":"0","endTime":"0","summary":"Soligenix highlighted HyBryte for cutaneous T-cell lymphoma as lead late-stage asset, citing statistically significant Phase 3 FLASH results with response rates rising to 49% by 18 weeks.Company reported confirmatory Phase 3 FLASH2 trial began enrolling in January 2025, with 66 of about 80 patients enrolled as of Feb. 10, 2026.Management flagged FLASH2 interim analysis targeted for 2Q2026, with top-line results expected in 2H2026.Presentation outlined additional rare-disease pipeline progress, including completed Phase 2a studies for SGX302 in mild-to-moderate psoriasis and SGX945 in Behet’s disease.Soligenix cited non-dilutive US government support for Public Health Solutions programs, including USD 30 million in NIH contract awards to date for RiVax ricin vaccine development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9CYpkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624683549","title":"Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2624683549","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624683549?lang=en_us&edition=fundamental","pubTime":"2026-04-03 00:00","pubTimestamp":1775145609,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 2nd, 2026, FinanceWire Soligenix (NASDAQ: SNGX) announced the publication of positive results fr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-publishes-positive-hybryte-study-results-in-oncology-and-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-publishes-positive-hybryte-study-results-in-oncology-and-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","QID","PSQ","TQQQ","GPIQ","FTEC","QYLG","JEPQ","IYW","QLD","QQQ","QQQY","MNQmain","NVIW.SI","SNGX","QDTE","QQQJ","QQQM","BK4139",".IXIC","QQQE","NQmain","SQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624575505","title":"Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624575505","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624575505?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:31","pubTimestamp":1775129477,"startTime":"0","endTime":"0","summary":"Soligenix reported publication of comparative clinical study results in Oncology and Therapy, following earlier disclosure of findings.Study found HyBryte outperformed Valchlor over 12-week course in patients with cutaneous T-cell lymphoma.HyBryte showed faster, more consistent lesion improvement, supporting its positioning as potential front-line topical option.Tolerability profile favored HyBryte, with fewer treatment-related skin reactions than Valchlor.Company is running confirmatory Phase 3 FLASH2 trial, with blinded interim analysis expected in 2Q2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3P3Nhp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624854866","title":"Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624854866","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624854866?lang=en_us&edition=fundamental","pubTime":"2026-04-02 00:30","pubTimestamp":1775061029,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, April 1st, 2026, FinanceWire Soligenix (NASDAQ:SNGX) reported 2025 results highlighting progress across its rare...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-highlights-phase-3-ctcl-progress-and-orphan-drug-milestones-in-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-highlights-phase-3-ctcl-progress-and-orphan-drug-milestones-in-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","QQQE","TQQQ","NDX","NVIW.SI",".IXIC","IYW","GPIQ","LU2065732104.USD","SNGX","BK4097","FTEC","PSQ","JEPQ","NQmain","QQQM","BK4139","QID","QDTE","SQQQ","QQQY","QQQ","QYLG","QQQJ","QLD","MNQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624561674","title":"Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624561674","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624561674?lang=en_us&edition=fundamental","pubTime":"2026-04-01 13:20","pubTimestamp":1775020806,"startTime":"0","endTime":"0","summary":"Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.56) by 48.75 percent. This is a 74.82 percent increase over losses of $(1.14) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51590086/soligenix-q4-eps-0-29-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551221","title":"Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551221","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551221?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:29","pubTimestamp":1774999792,"startTime":"0","endTime":"0","summary":"Soligenix Inc reports results for the quarter ended December 31 - Earnings SummarySoligenix Inc SNGX.OQ reported a quarterly adjusted loss of 28 cents per share for the quarter ended December 31, high","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J2LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624371385","title":"Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2624371385","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624371385?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:08","pubTimestamp":1774987734,"startTime":"0","endTime":"0","summary":"Soligenix posted a net loss of $11 million, a 34% wider loss.Research and development expenses climbed 43% to $7.5 million, driven by costs tied to the Phase 2a Behet's disease study and the confirmatory Phase 3 HyBryte CTCL trial.Cash and cash equivalents edged up 1% to $7.9 million, while working capital rose to $5.1 million.Company expects top-line results for the Phase 3 FLASH2 HyBryte study in the second half of 2026, with cash runway projected into the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8zMrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623535330","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2623535330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623535330?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:30","pubTimestamp":1774971010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA), PolyPid (PYPD) and Soligenix (SNGX)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-84?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-84?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLSX","BLSG","PYPD","SNGX","LU0029874061.USD","BK4137","BK4007","LU0128526141.USD","BK4581","BK4588","BK4112","BK4585","IVA","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858503","title":"BRIEF-Soligenix Announces Recent Accomplishments And Year End 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623858503?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:40","pubTimestamp":1774957200,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Announces Recent Accomplishments And Year End 2025 Financial ResultsSoligenix Inc SNGX.O:SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR END 2025 FINANCIAL RESULTSSource text: ID:nPn3t9xShaFurther company coverage: SNGX.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUAB5MW3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896358","title":"Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896358?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:57","pubTimestamp":1774555060,"startTime":"0","endTime":"0","summary":"Soligenix said it is focused on developing and commercializing treatments for rare diseases, with operations organized into Specialized BioTherapeutics and Public Health Solutions segments.For HyBryte in cutaneous T-cell lymphoma, the company cited a statistically significant Phase 3 primary endpoint with p=0.04 and reported a 49% response rate after 18 weeks of treatment in the FLASH study.Soligenix said the confirmatory Phase 3 FLASH2 study began enrollment in January 2025 and had enrolled 66 of about 80 patients as of Feb. 10, 2026.For SGX302 in mild-to-moderate psoriasis, the company said a Phase 2a study was completed with clinical success observed using both ointment and gel formulations.Soligenix said it has received NIH contract awards of USD 30 million to date supporting its ricin vaccine program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbLXfWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622862597","title":"Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622862597","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622862597?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:00","pubTimestamp":1774540823,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 26th, 2026, FinanceWire Soligenix (NASDAQ:SNGX) announced the European Commission has granted orphan ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-receives-eu-orphan-drug-designation-for-dusquetide-in-behcet-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/soligenix-nasdaq-sngx-receives-eu-orphan-drug-designation-for-dusquetide-in-behcet-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPIQ","QDTE","PSQ","QQQJ","QID","NVIW.SI","QLD","QQQY","JEPQ","IYW","FTEC","BK4139","MNQmain",".IXIC","TQQQ","SQQQ","QQQE","SNGX","BK4156","QYLG","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854244","title":"Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854244","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854244?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:36","pubTimestamp":1774524984,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenixs-sgx945-granted-european-orphan-drug-designation-in-behcets-disease-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenixs-sgx945-granted-european-orphan-drug-designation-in-behcets-disease-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854268","title":"Soligenix shares rise; European Commission grants orphan drug designation for SGX945 in Behçet's disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854268?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:31","pubTimestamp":1774524676,"startTime":"0","endTime":"0","summary":"European Commission granted orphan drug designation to Soligenix’s dusquetide  for the treatment of Behet's disease, following a positive recommendation from the EMA’s Committee for Orphan Medicinal Products.The designation provides 10-year marketing exclusivity in the EU after approval and access to the centralized authorization procedure.SGX945 previously received orphan drug and fast track designations from the FDA for Behet's disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3WCnSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}